Highest-materiality recent filing
Sanara MedTech Q1 net revenue up 19% to $27.8M; GAAP EPS $0.04 vs ($0.07) loss
Net income from continuing ops of $0.4M ($0.04 diluted EPS) vs loss of $0.6M ($0.07) YoY.
Sanara MedTech Q4 revenue $27.5M (+5% YoY); FY25 rev $103.1M (+19%); reaffirms FY26 guidance
Net revenue Q4 2025 $27.5M (+5% YoY); excluding $1.8M prior-year BIASURGE hurricane sales, growth was 13%.
Sanara MedTech reports preliminary FY 2025 revenue ~$103M, guides FY 2026 revenue $116M-$121M
Q4 2025 net revenue expected $27.2M-$27.7M, up 3-5% YoY; excluding $1.8M BIASURGE sales in Q4'24, growth 11-13%.
Sanara MedTech discontinues Tissue Health Plus, reallocates resources to surgical business
Completed evaluation of strategic alternatives for THP; ceased development in late September and will discontinue operations.
Sanara MedTech Q3 revenue +22% to $26.3M; net income from continuing ops positive; THP discontinued
Q3 net revenue $26.3M (+22% YoY); net income from continuing ops $0.8M vs loss $0.2M; Adj. EBITDA $4.9M (+$2.3M).
Sanara MedTech appoints Seth Yon as CEO; Nixon remains Executive Chairman
Seth Yon promoted from President/Chief Commercial Officer to President/CEO and director, effective Sept 15, 2025.
Net revenue $25.8M, up 28% YoY; net loss narrowed to $2.0M from $3.5M.
Sanara MedTech Q1 revenue up 26% to $23.4M; net loss widens to $3.5M
Net revenue $23.4M (+26% YoY); net loss $3.5M vs $1.8M loss in Q1 2024.
Sanara MedTech acquires CarePICS for $2M cash plus $1.65M debt; draws $12.25M loan
Acquired all equity of CarePICS, a wound care telehealth platform, for $2M cash plus $1.65M debt payoff.
Sanara MedTech Q4 net revenue up 49% to $26.3M; net loss widens to $1.7M
Q4 net revenue $26.3M (+49% YoY); full year $86.7M (+33% YoY).
Exclusive U.S. license/distribution for OsStic and ARC delivery tech; initial five-year term with renewal options.
Sanara MedTech reports Q4 prelim net revenue up 45-48% YoY; FY up 32-33%
Q4 2024 net revenue expected $25.7M-$26.2M, a 45-48% increase YoY.
Sanara MedTech Q3 revenue up 35% to $21.7M, net loss widens to $2.9M
Net revenue rose 35% YoY to $21.7M; net loss of $2.9M vs $1.1M loss in Q3 2023.
Sanara MedTech formalizes CEO Ronald Nixon employment agreement with $350K salary
Base salary of $350,000, one-time cash bonus of $125,000, and annual stock award potential up to 75% of salary.
Sanara invests $5M for 6.6% of ChemoMouthpiece, exclusive U.S. distribution via InfuSystem JV
Sanara CMP purchased 100,674.72 common units in ChemoMouthpiece for $5.0 million, a 6.64% ownership stake.
Sanara Q2 revenue up 28% to record $20.2M; net loss widens to $3.5M
Revenue $20.2M, +28% YoY; eleventh consecutive record revenue quarter.
Sanara MedTech Inc. CEO Zachary B. Fleming Resigns, Enters Separation Agreement
Zachary B. Fleming resigned as CEO effective May 10, 2024; separation agreement signed May 29, 2024.
Sanara MedTech Q1 revenue record $18.5M; CEO Fleming resigns, Chairman Nixon takes over
Net revenue $18.5M in Q1 2024, up 19% YoY; tenth consecutive record quarter.
Sanara MedTech enters $55M non-dilutive term loan with CRG; repays $9.8M existing debt
New $55M term loan with CRG Servicing LLC; $15M drawn at close, up to $40M available in two tranches before June 30, 2025.
Sanara MedTech appoints Jake Waldrop COO and Tyler Palmer Chief Corporate Development Officer
Jake Waldrop appointed COO effective April 15, 2024; base salary $315,000, eligible for annual restricted stock and cash bonus up to 75% of salary.
Sanara MedTech revenue up 42% to $65M in FY2023; net loss narrows to $4.4M
FY2023 net revenue of $65.0M, up 42% from $45.8M in FY2022.
Sanara MedTech Q4 revenue $17.7M, up 15.5% YoY; FY23 revenue $65.0M, up 41.8% YoY
Q4 net revenue $17.7M, +15.5% YoY; ninth consecutive record quarter.
Sanara MedTech Q3 revenue $16M (record), net loss narrows to $1.1M, Adj. EBITDA positive $0.3M
Q3 net revenue $16.0M, up 23% YoY; net loss $1.1M vs $1.5M loss a year ago.
Sanara MedTech Q2 revenue up 63% to $15.8M; acquires collagen assets to cut royalties
Q2 2023 net revenues $15.8M (+63% YoY); net loss $1.9M vs net income $0.8M in prior year.
Sanara MedTech acquires collagen assets for $15.25M; funds with $12M loan from Cadence Bank
Acquired IP, manufacturing rights, and four 510(k)-cleared products including CellerateRX and HYCOL.
Sanara MedTech Q1 revenue $15.5M, up 99% YoY; net loss narrows to $1.2M
Net revenues $15.5M (99% YoY increase); net loss $1.2M vs $3.2M prior year.
Sanara MedTech FY2022 revenue $45.8M (+90% YoY); net loss $8.1M
Net revenue $45.8M vs $24.1M in 2021, a 90% increase; gross margin 86% vs 90%.
Sanara MedTech Q4 revenue jumps 119% YoY to $15.3M; full-year revenue up 90% to $45.8M
Net revenue $15.3M in Q4 2022 (up 119% from $7.0M); full-year $45.8M (up 90% from $24.1M).
On the Effective Date, Elizabeth B. Taylor, the Company’s Chief Financial Officer, will assume Mr. McNeil’s duties as principal accounting officer.
On May 19, 2025, Michael D. McNeil notified Sanara MedTech Inc. (the “Company”) that he is retiring from his position as Chief Accounting Officer and Chief Administrative Officer of the Company, effective August 19, 2025
On January 15, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) appointed Elizabeth B. Taylor to serve as the Chief Financial Officer of the Company, including the role of principal financial officer, effective as of the Effective Date.
On October 4, 2024, James W. Stuckert notified Sanara MedTech Inc. (the “Company”) of his intention to resign from his position as a member of the Company’s Board of Directors (the “Board”) and each of its committees upon which he serves, effective as of October 4, 2024.
On October 4, 2024, the Board appointed Keith Myers as a director of the Company, effective October 4, 2024 (the “Effective Date”), to fill the vacancy resulting from Mr. Stuckert’s resignation.
Zachary B. Fleming tendered his resignation as the Chief Executive Officer of Sanara MedTech Inc. (the “Company”), effective as of such date
On May 12, 2024, the Board appointed Ronald T. Nixon, the Company’s Executive Chairman, as the Chief Executive Officer of the Company, effective immediately.
On May 10, 2024 (the “Effective Date”), Zachary B. Fleming delivered notice to the Board of Directors of the Company (the “Board”) that he is resigning from his position as Chief Executive Officer of the Company, effective immediately.
On April 5, 2024, Sanara MedTech Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company appointed Mr. Jacob A. Waldrop as the Chief Operating Officer of the Company, effective April 15, 2024 (the “Effective Date”).
On December 2, 2022 (the “Effective Date”), Shawn M. Bowman tendered his resignation as President, Strategic Partnerships of Sanara MedTech Inc. (the “Company”), effective immediately.
appointed Mr. Zachary B. Fleming as the Chief Executive Officer of the Company, effective January 1, 2022.
On December 22, 2021, the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) appointed Mr. Zachary B. Fleming as the Chief Executive Officer of the Company, effective January 1, 2021 (the “Effective Date”).
Max materiality 0.85 · Median 0.60 · Most common event earnings